OTC: DPHAY - Dechra Pharmaceuticals PLC

Yield per half year: 0%
Dividend yield: 0.00%

Share chart Dechra Pharmaceuticals PLC


About Dechra Pharmaceuticals PLC

DECHRA PHARMACEUTICALS LIMITED develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases.

more details
It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. DECHRA PHARMACEUTICALS LIMITED was incorporated in 1997 and is headquartered in Northwich, United Kingdom. As of January 16, 2024, DECHRA PHARMACEUTICALS LIMITED was taken private.

ISIN US2434351043
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета gbp
Див.доход ао 0.3186
Дивиденд ао 98.88
Сайт https://www.dechra.com
Цена ао 98
Change price per 3 year: +41.01% (69.5)
Change price per 5 year: +41.01% (69.5)

Underestimation

Title Value Grade
P/S 5.51 2
P/BV 5.55 2
P/E 53.05 2
EV/EBITDA 47.14 1
Total: 2.63

Efficiency

Title Value Grade
ROA, % -1.78 0
ROE, % -3.69 0
Total: 0.8333

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.7143 7.14
Total: 4.31

Debt

Title Value Grade
Debt/EBITDA 5.01 0
Total: 6

Growth impulse

Title Value Grade
Yield Revenue, % 58.05 7
Yield Ebitda, % -19.98 0
Yield EPS, % -233.04 0
Total: 1.4

Head Job title Payment Year of birth
Mr. Ian D. Page CEO, MD & Executive Director 1.08M 1961 (64 years)
Mr. Paul Nicholas Sandland MAAT, FCCA CFO & Executive Director 710.1k 1979 (46 years)
Mr. Patrick Meeus Chief Scientific Officer N/A
Mr. Jamie Adams Chief Information Officer N/A
Ms. Katy Clough Chief People Officer N/A
Mr. Mike Eldred President of North America N/A 1970 (55 years)
Ms. Melanie Jane Hall Company Secretary N/A

Address: United Kingdom, Northwich, 24 Cheshire Avenue - open in Google maps, open in Yandex maps
Website: https://www.dechra.com